
1. eur rev med pharmacol sci. 2020 jul;24(13):7412-7419. doi:
10.26355/eurrev_202007_21909.

vorinostat potential antiparasitic drug.

herrera-martínez m(1), orozco-samperio e, montaño s, ariza-ortega ja,
flores-garcía y, lópez-contreras l.

author information: 
(1)instituto de farmacobiología, universidad de la cañada, paraje titlacuatitla, 
teotitlán de flores magón, oaxaca, méxico. luilli_lopez@uaeh.edu.mx.

objective: vorinostat drug used treat cutaneous cell lymphoma whose
action mechanism based histone deacetylase inhibition. histone deacetylases
are family enzymes remove acetyl groups histone non-histone
proteins control many crucial processes, gene regulation, cell cycle
progression, differentiation, apoptosis. histone deacetylase homologues are
also expressed parasites genus plasmodium, leishmania, cryptosporidium,
schistosoma, entamoeba, others. way, antiparasitic properties of
vorinostat explored. aim review report current
state knowledge vorinostat antiparasitic drug plasmodium,
leishmania, cryptosporidium, schistosoma entamoeba order support future
investigation field.
materials methods: authors revised recent relevant literature
concerning topic discussed advances limitations studies on
vorinostat potential drug treat human parasitic diseases.
results: vorinostat efficient vitro and, cases, vivo,
against parasites cause parasitic diseases, malaria, leishmaniasis, 
cryptosporidiosis, amoebiasis, schistosomiasis.
conclusions: vitro vivo models demonstrated antiparasitic
activity vorinostat, however, challenge assay activity animal
models evaluate vorinostat safe humans new alternative to
treat human parasitic infections.

doi: 10.26355/eurrev_202007_21909 
pmid: 32706080 

